EP0460064A1 - Compositions aerosol therapeutiques - Google Patents

Compositions aerosol therapeutiques

Info

Publication number
EP0460064A1
EP0460064A1 EP90904101A EP90904101A EP0460064A1 EP 0460064 A1 EP0460064 A1 EP 0460064A1 EP 90904101 A EP90904101 A EP 90904101A EP 90904101 A EP90904101 A EP 90904101A EP 0460064 A1 EP0460064 A1 EP 0460064A1
Authority
EP
European Patent Office
Prior art keywords
thr
leu
ser
gly
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90904101A
Other languages
German (de)
English (en)
Other versions
EP0460064A4 (en
Inventor
George Robert 1485 Ashford Avenue Felt
Mark Peter Warchol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rorer International Holdings Inc
Original Assignee
Rorer International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer International Holdings Inc filed Critical Rorer International Holdings Inc
Publication of EP0460064A1 publication Critical patent/EP0460064A1/fr
Publication of EP0460064A4 publication Critical patent/EP0460064A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Definitions

  • the present invention relates to a novel therapeutic self-propelled aerosol formulation for inhalation. More particularly, it relates to a therapeutic formulation of the dispersion or suspension type comprising: a physiologically active solid drug and a solid extender or carrier for the drug suspended in a chlorofluorocarbon propellant mixture.
  • the present invention also relates to a process for the preparation of self-propelled aerosol formulation intended for inhalation wherein the preparative steps include: dissolving a solid drug and a solid extender or carrier in a solvent; lyophilizing the solution to obtain a powder; micronizing and suspending the powder in a propellant mixture.
  • the preferred embodiment of the present invention relates to a self-propelled aerosol formulation for inhalation wherein the active drug is a polypeptide having calcitonin activity for the treatment of bone diseases.
  • Inhalation therapy involves direct deposition of medication onto the airway of a patient by the nasal or oral routes.
  • This method of delivery of medication is therapeutically sound and is well accepted in the prior art.
  • the benefits of the method are: the rapid medication effects essential in the treatment of life threatening afflictions, such as certain allergic and asthmatic conditions; the reduction of systemic side effects; convenience and cost as compared to, for example, intravenous or intramuscular administration; and self-administration of certain drugs such as the pharmaceutically active peptides that cannot be taken orally for reason of decomposition in the gastrointestinal tract.
  • Inhalation therapy can be used for the treatment of a variety of diseases requiring physiologically active drugs such as insulin, calcitonin, interferons, vaccines, decongestants, antiasth atics and the like.
  • physiologically active drugs such as insulin, calcitonin, interferons, vaccines, decongestants, antiasth atics and the like.
  • Particle penetration and deposition are believed to maximized by the use of a particle size range of from about 2 to about lO ⁇ . Particles less than 2 ⁇ , although reach the alveoli, deposit minimally and are likely to be exhaled. Particles lO ⁇ or greater do not enter the respiratory tract and are deposited in the oropharynx. Comminuting solid drugs to obtain the desired particle size range poses no problem in the prior art. However, the requirements of particle stability, precise dosage and non-irritation have not been, in general, quite satisfactorily met. Generally described, the heretofore proposed and/or utilized aerosol formulations, are micronized drug particles suspended in a propellant mixture.
  • the formulations also contain a surfactant, a solvent or a dispersing agent to prevent agglomeration or sedimentation of the suspended particles.
  • a surfactant e.g., sodium bicarbonate
  • a solvent or a dispersing agent e.g., sodium bicarbonate
  • the drug particles tend to form agglomerates, floating flocculants or sedimentary precipitations during extended shelf-life resulting in destruction or clogging of the dispensing mechanism, and when administered, uneven distribution and non-uniform dosage of the drug in the tracheobronchial tree of the patient.
  • certain solvents and surfactants tend to cause irritation on extended use of the formulations.
  • a self-propelled therapeutic aerosol formulation for oral and/or intranasal application comprising:
  • said homogeneous complex is insoluble in said propellant mixture and is present in the form of micronized solid particles of which at least 90% w/w has an effective particle diameter of about 2 to about lO ⁇ and having a density of about 1.33 to about 1.40 gm/cc.
  • the active drug and the pharmaceutically acceptable extender are dissolved in water, the resultant solution is lyophilized forming a homogeneous complex wherein the drug and extender molecules are in intimate contact with each other.
  • the so obtained powder is comminuted to the desired particle size, then combined with a small amount of solvent and/or surfactant, followed by metering into aerosol containers and adding the propellant mixture thereto.
  • the desired, self-propelled therapeutic formulations can be obtained as described above and as will be further explained and exemplified in detail.
  • the extenders serve as carriers and diluents for the active drugs in the formulations and comprise about 75 to 99.9% of the drug/extender homogeneous complex.
  • the extender must be a solid, water soluble, propellant insoluble, pharmaceutically acceptable material, so that it can be dissolved in an aqueous solution together with the active drug, lyophilized and the so obtained homogeneous complex comminuted to the desired particle size.
  • a) other amino acids including D or L-Methionine, glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, serine, cystein, aspartic acid, glutamic acid, arginine, lysine, asparagine, histidine, tryptophan and proline;
  • monosaccharides such as, D-allose, D-altrose, fructose, galactose, glucose, inositol, D-mannose and sorbose;
  • disaccharides such as, sucrose, cellobiose, lactose, maltose, melibiose, trehalose and turanose;
  • polysaccharides such as, dextrin, glycogen and starch
  • peptides and proteins such as the widely used dipeptide, Aspartame.
  • the present invention utilizes from about 0.1 to about 3.0% w/w of a solvent and/or surfactant to help maintain a stable suspension.
  • the solvents used include alcohols, preferably ethyl alcohol; while the surfactants include nonionic, cationic and anionic surface active agents, the preferred being oleic acid.
  • the propellant mixture comprises from about 92 to about 99.89% w/w of the total formulation having a density of about 1.33 to 1.40 gm/cc and consists of a 90/10 mixture of dichlorodifluoromethane and dichlorotetrafluoroethane, or a 90/10 mixture of dichlorodifluoromethane and trichlorofluoromethane, sold under the trade names Dymel 12, Dymel 114 and Dymel 11 respectively.
  • the active drug comprises from about 0.1 to about 25.0% w/w of the drug/extender homogeneous complex.
  • Drugs in solid form and drugs that can be made into a solid form and are soluble in aqueous solutions and insoluble in the hydrocarbon mixtures hereindescribed are contemplated for use in accordance with the present invention.
  • bronchodilators such as:
  • Ipratropium bromide 3-(3-hydroxy-l-oxo-2- phenylpropoxy)-8- methyl-8-(1-methylethyl)-3-azonicabicyclo[3.2.1]octane bromide;
  • Metaproterenol sulfate 5-[l-hydroxy-2-[ (1-methylethyl) amino]ethyl]1,3-benzenediol sulfate;
  • Terbutaline sulfate 5-[2-[(1,1-dimethylethyl)amino]-1- hydroxyethyl]-1,3-benzenediol sulfate;
  • Bitolterol mesylate 4-methylbenzoic acid 4-[2-[(l,l- dimethylethyl)amino]-1-hydroxyethyl]-1,2-phenylene ester mesylate;
  • Isoproterenol hydrochloride 4-[l-hydroxy-2-[ (1-methyl ⁇ ethyl)amino]ethyl]-1,2-benzenediol hydrochloride;
  • Epinephrine hydrochloride 4-[l-hydroxy-2(methylamino)- ethyl]-1,2-benzenediol hydrochloride;
  • Albuterol sulfate a•-[[(1,1- dimethylethyl)amino]methyl]- 4-hydroxy-l,3-benzenedimethanol sulfate;
  • Theophylline 3,7-dihydro-l,3-dimethyl-lH-purine-2,6- dione.
  • Cardiovascular drugs such as:
  • Clonidine hydrochloride 2,6-dichloro-N-2- imidazolidinyli- denebenzeneamine hydrochloride
  • Terazosin hydrochloride l-(4-amino-6,7-dimethoxy-2- quina- zolinyl)-4[ (tetrahydro-2-furanyl)carbonyl) ]piperazine hydrochloride;
  • Prazosin hydrochloride l-(4-amino-6,7-dimethoxy-2- quina- zolinyl)-4-(2-furoyl)piperazine hydrochloride;
  • Tolazoline hydrochloride 4,5-dihydro-2-(phenylmethyl)- lH-imidazole monohydrochloride
  • Labetalol hydrochloride 5-[l-hydroxy-2-[ (l-methyl-3- phenylpropyl)amino]ethyl]salicylamide monohydrochloride;
  • Captopril 1-[ (2S)-3-mercapto-2-methylpropionyl]-L- proline;
  • Verapamil hydrochloride ⁇ -[3-[[2-(3,4-dimethoxyphenyl)- ethyl]-methylamino]propy1]-3,4-dimethoxy- ⁇ (1- methylethyl)benzene-acetonitrile hydrochloride;
  • Diltiazem hydrochloride 3-(acetyloxy)-5-[2-(dimethyl- mino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5- benzothiazepin-4(5H)-one hydrochloride;
  • Propranolol hydrochloride l-(isopropylamino)-3-(l- napthyl-oxy)-2-propanol hydrochloride;
  • Bretylium tosylate (o-bromobenzyl) ethyl dimethylammonium p-toluene solfonate;
  • Lidocaine hydrochloride 2-(diethylamino)-2• ,6'- acetoxyl-idide monohydrochloride;
  • Mexilitine hydrochloride l-methyl-2-(2,6-xylyloxy)- ethyl-amine hydrochloride;
  • Disopyramide phosphate ⁇ -[2-diisopropylamino)ethyl]-c_- phenyl-2-pyridineacetamide phosphate;
  • Procainamide hydrochloride p-amino-N-[2-(diethylamino)- ethyl]-benzamide hydrochloride;
  • Flecainide acetate N-(2-piperidinylmethyl)-2,5- bis(2,2,2-trifluoroethoxy)benzamide monoacetate;
  • Tocainide hydrochloride 2-amino-N-(2,6-dimethylphenyl)- propanamide hydrochloride
  • Methoxamine hydrochloride ⁇ -(l-aminoethyl)-2,5- dimethoxy-benzenemethanol hydrochloride;
  • Minoxidil 6-(l-piperidinyl)-2,4-pyrimidinediamine-3- oxide
  • Metoprolol tartrate l-(isopropylamino)-3-[p-(2-methoxy- ethyl)phenoxy]-2-propanol (2:1) dextro-tatrate salt;
  • Hydroflumethiazide 3,4-dihydro-6-(trifluoromethyl)-2H- 1,2,4-benzothiadiazine-7-sulfonamide-l,1-dioxide;
  • Amrinone lactate 5-amino[3,4*-bipyridine]-6(lH)-one 1actate;
  • Ethaverine hydrochloride l-[(3,4- diethoxyphenyl)methyl]-6,7-diethoxyisoquinoline hydrochloride;
  • Papaverine hydrochloride l-[(3,4- dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline hydrochloride.
  • the preferred embodiment of the invention utilizes calcitonin as the active polypeptide for the treatment of bone diseases.
  • Calcitonin is a polypeptide hormone involved in the control of calcium metabolism in the body. All known natural calcitonin peptides contain an amino acid sequence of 32 amino acids, of which the seven at the amino terminal end of the peptide chain are held in a cyclic configuration by a sulphur or carbon bridge and the carboxyl terminal residue consists of proline amide.
  • the natural calcitonins include the salmon, eel, bovin, porcine, ovine, rat and human calcitonin.
  • salmon calcitonin is of special interest in view of its relatively hydrophilic character and its stability. Salmon calcitonin has the following formula:
  • the level of hypocalcemic activity of calcitonin varies from species to species.
  • Salmon and chicken calcitonin have a potency of about 4,000 to 6,000 MCR (Medical Research Council) ⁇ /mg peptide; eel calcitonin about 2,000 to 4,000 MRC U/mg peptide; rat 400 MRC ⁇ /mg; while beef, sheep, hog and man about 100 to 200 MRC ⁇ /mg peptide.
  • Calcitonin used by the present invention may be obtained from Armour Pharmaceutical Co. , from natural sources, or by synthetic routes known in the art. The synthesis can be performed by classical peptide synthesis as well as by solid phase synthesis.
  • the present invention encompasses synthetic calcitonin peptides having biological activity of the same type as those above- described.
  • synthetic calcitonin are disclosed, along with processes for preparation thereof in the following U.S. Pat. Nos.
  • Synthetic calcitonin analogues disclosed in these patents are incorporated herein by reference as if set out in full herein. This list is not intended to be exhaustive of all U.S. Patents covering synthetic calcitonin analogues, but is representative of the analogues useful in the present invention; nor is the invention limited to the compounds disclosed in the listed patents.
  • analogues of calcitonin constitute specific active ingredients used in the various suppository formulations of the present invention:
  • Des-2-Serine, 3-Asparagine Calcitonin having the following structures:
  • G-Serine, Des-19-Leucine Calcitonin having the following structures:
  • Salmon Calcitonin having the following structures:
  • Des-Leu 16 -Calcitonin having the following structures:
  • Leucine 22 - Calcitonin having the following structures:
  • Glycine - 8 Calcitonin having the following structures:
  • Glycine 8 -D-Arginine 24 Calcitonin having the following structures:
  • L-Tyrosine 21 Calcitonin having the following structures
  • D-Arginine 24 Calcitonin having the following structures:
  • N ⁇ -Propionyl, l,7-Di-Alanine, Des-19-Leucine Calcitonin having the following structure:
  • the active drug and the extender both being in a solid form, are dissolved in water by means of mechanical mixing, followed by lyophilization and comminution to the desired particle size, using well-known technique employed in the prior art.
  • the drug/extender complex at least 90% of which possess an effective particle diameter of about 2 to 10 ⁇ is combined with a solvent or surfactant by means of blending and metered into a suitable aerosol container.
  • the desired amount of the 90/10 dichlorodifluoromethane/ dichlorotetrafluoroethane is charged into the container to complete the process in making the self-propelled formulation.
  • micronized calcitonin/DL-Methione complex was then combined with oleic acid and a 90/10 blend of Dymel 12/Dymel 114 in a suitable container.
  • the so prepared formulation was found to contain:
  • Dose delivery was found to contain an average of 7.32 ⁇ g of calcitonin and 1063 ⁇ g DL-Methionine per actuation, while content uniformity was found to be an average of 1.795 ⁇ g/unit of calcitonin and 259.2 ⁇ g/unit DL-Methionine.
  • Particle size measurement showed an M50 of 4.4 ⁇ and an M90 of 13.5 ⁇ .
  • a calcitonin/DL-Methionine complex was prepared and processed as in Example 1.
  • the final formulation contained 0.125 grams of calcitonin/DL-Methionine, 0.095 grams of oleic acid and 16.148 grams of 90/10 mixture of Dymel 12/Dymel 114.
  • Dose delivery was found to be 22.5 ⁇ g of calcitonin and 477.5 ⁇ g of DL-Methionine per actuation.
  • a slurry was prepared consisting of 20.0 grams of DL- Methionine/SCT, 40.0 grams of absolute ethanol, and 40.0 grams of oleic acid. 250 ml of the slurry was then combined with 9.75 ml of 90/10 of Dymel 12/Dymel 114 propellant blend to produce the following self-propelled aerosol suspension:
  • the formulation provides 200 IU/50 ⁇ L per actuation.
  • a slurry was then prepared using the micronized powder, 15 grams of SPAN 85 and 120 grams of ethanol. The slurry was then combined with a propellant mixture containing 3,000 grams of Dymel 114 and 12,000 grams of Dymel 12.
  • the formulation had the following composition:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions aérosol thérapeutiques auto-propulsées, et un procédé pour leur préparation. Elles consistent en un complexe homogène insoluble dans l'agent propulseur, soluble dans l'eau, de particules de l'ordre du micron d'un médicament et d'un diluant en suspension dans un mélange propulseur.
EP19900904101 1989-02-23 1990-02-21 Therapeutic aerosol formulations Withdrawn EP0460064A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31460589A 1989-02-23 1989-02-23
US314605 1994-09-28

Publications (2)

Publication Number Publication Date
EP0460064A1 true EP0460064A1 (fr) 1991-12-11
EP0460064A4 EP0460064A4 (en) 1992-04-01

Family

ID=23220626

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900904101 Withdrawn EP0460064A4 (en) 1989-02-23 1990-02-21 Therapeutic aerosol formulations

Country Status (6)

Country Link
EP (1) EP0460064A4 (fr)
JP (1) JPH05508616A (fr)
AU (1) AU5194990A (fr)
CA (1) CA2050905A1 (fr)
FI (1) FI913899A0 (fr)
WO (1) WO1990009781A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562125A4 (fr) * 1991-10-11 1994-03-18 Toray Industries Composition a base d'anticorps.
WO1993013752A1 (fr) * 1992-01-21 1993-07-22 Sri International Procede ameliore de preparation de medicaments polypeptides sous forme de poudre
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5698672A (en) * 1995-04-04 1997-12-16 Zymogenetics, Inc. Synthetic calcitonin mimetics
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540982B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6468507B1 (en) 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6464959B1 (en) 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
US6749845B2 (en) 2001-02-15 2004-06-15 Aeropharm Technology, Inc. Modulated release particles for lung delivery
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2176251B1 (fr) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. Indazoles substitués par la 5-pyridinone et compositions pharmaceutiques les contenant
EP2674417A3 (fr) 2007-11-21 2014-04-09 Decode Genetics EHF Inhibiteurs de pde4 biaryle pour le traitement de l'inflammation
EP2077132A1 (fr) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispositif distributeur, dispositif de stockage et procédé pour la distribution d'une formulation
CN101945872B (zh) 2008-01-11 2014-07-23 阿尔巴尼分子研究公司 作为mch拮抗剂的(1-吖嗪酮)-取代的吡啶并吲哚
US8297305B2 (en) 2008-01-28 2012-10-30 Kohler Co. Valve assembly having an improved flow path
WO2010059836A1 (fr) 2008-11-20 2010-05-27 Decode Genetics Ehf Composés bicycliques substitués à pont aza pour maladie cardiovasculaire et du système nerveux central
AU2010207486B2 (en) 2009-01-26 2013-03-07 Israel Institute For Biological Research Bicyclic heterocyclic spiro compounds
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239B1 (fr) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adaptateur, dispositif d'inhalation et pulvérisateur
UA107097C2 (en) 2009-11-25 2014-11-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Dispenser
WO2011064163A1 (fr) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nébuliseur
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2694220B1 (fr) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Appareil médical pourvu d'un récipient
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (fr) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Pulvérisateur comprenant des moyens de détrompage
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
EP3030298B1 (fr) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nébuliseur
UA121114C2 (uk) 2014-05-07 2020-04-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх Небулайзер, індикаторний пристрій і контейнер
ES2874029T3 (es) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizador
ES2954961T3 (es) 2014-05-07 2023-11-27 Boehringer Ingelheim Int Unidad, nebulizador y método
CA3093340A1 (fr) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Composes inhibiteurs de kinase, compositions et procedes d'utilisation
EP3846792A4 (fr) 2018-09-06 2022-10-12 Innopharmascreen Inc. Procédés et compositions pour le traitement de l'asthme ou de la maladie de parkinson
EP3906233B1 (fr) 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Composés inhibiteurs de kinase, compositions et procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB837465A (en) * 1957-01-31 1960-06-15 Riker Laboratories Inc Self-propelling, powder-dispensing compositions
GB994734A (en) * 1962-10-30 1965-06-10 Riker Laboratories Inc Self-propelling powder-dispensing compositions
JPS60161924A (ja) * 1984-02-01 1985-08-23 Fujisawa Pharmaceut Co Ltd 肺吸収用組成物
EP0302772A1 (fr) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin pour administration nasale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241051A (en) * 1977-11-04 1980-12-23 Christie Robert B Calcitonin
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0223831B1 (fr) * 1985-05-22 1992-07-15 Liposome Technology, Inc. Procede et systeme d'inhalation de liposomes
NL8602950A (nl) * 1985-12-04 1987-07-01 Sandoz Ag Calcitonine-derivaten en werkwijzen voor het bereiden van deze derivaten en van farmaceutische preparaten die ze bevatten.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB837465A (en) * 1957-01-31 1960-06-15 Riker Laboratories Inc Self-propelling, powder-dispensing compositions
GB994734A (en) * 1962-10-30 1965-06-10 Riker Laboratories Inc Self-propelling powder-dispensing compositions
JPS60161924A (ja) * 1984-02-01 1985-08-23 Fujisawa Pharmaceut Co Ltd 肺吸収用組成物
EP0302772A1 (fr) * 1987-08-03 1989-02-08 Asahi Kasei Kogyo Kabushiki Kaisha Calcitonin pour administration nasale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
K. PARKITT et al.: "MARTINDALE - THE EXTRA PHARMACOPOEIA", Twenty-ninth edition, edited by J.E.F. Reynolds, January 1989, The Pharmaceutical Press, London, GB; *
PATENT ABSTRACTS OF JAPAN, vol. 9, no. 331 (C-321)(2054), 25th December 1985; & JP-A-60 161 924 (FUJISAWA YAKUHIN KOGYO K.K.) 23-08-1985 *
See also references of WO9009781A1 *

Also Published As

Publication number Publication date
EP0460064A4 (en) 1992-04-01
AU5194990A (en) 1990-09-26
FI913899A0 (fi) 1991-08-19
CA2050905A1 (fr) 1990-08-24
WO1990009781A1 (fr) 1990-09-07
JPH05508616A (ja) 1993-12-02

Similar Documents

Publication Publication Date Title
EP0460064A1 (fr) Compositions aerosol therapeutiques
AU688283B2 (en) Pulmonary delivery of active fragments of parathyroid hormone
KR100419037B1 (ko) 폐를통한인슐린의전달방법및그조성물
JP2747073B2 (ja) ヒト成長ホルモン製剤
SK76797A3 (en) Therapeutic preparation for inhalation containing parathyroid hormone, pth
JP2005537232A (ja) アミリンアゴニストペプチドの製剤
PT706383E (pt) Composicoes para inalacao
SK283147B6 (sk) Práškový prostriedok na aplikáciu liečivých peptidov, spôsob jeho výroby a jeho použitie
JPH07165613A (ja) 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物
US20090203576A1 (en) Methods and compositons for pulmonary delivery of insulin
JPH09315953A (ja) 経鼻吸収用生理活性ペプチド組成物
JP2007161702A (ja) 水性吸入用医薬組成物
WO1997007816A1 (fr) Solution contenant l'igf-i

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910819

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19920211

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 19930209

18W Application withdrawn

Withdrawal date: 19930215